GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives Indication: Study Investigators/Centers: Research Methods Data Source:

Size: px
Start display at page:

Download "GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives Indication: Study Investigators/Centers: Research Methods Data Source:"

Transcription

1 GSK Medicine: Study Number: Title: OCSIGEN study Longitudinal follow-up of a cohort of patients with asthma treated with inhaled corticosteroids in primary care Rationale: In the Post-Licensing File of 20 December 200 for proprietary drugs containing fluticasone propionate, signed on April 2 nd 2003, GlaxoSmithKline undertook to conduct an observational study to assess how inhaled corticosteroids (ICS) were used in real-world conditions. This comprised two panels, one in a primary care setting (general practitioner; GP) and the other in a specialist care setting (chest physician; CP) in France. National and international consensus guidelines (Global Initiative for Asthma, GINA) provide recommendations for asthma management as a function of disease severity. In order to propose appropriate asthma controller therapy, asthma severity should thus be assessed regularly. Treatment decisions are based on the level of asthma control assessed over a few weeks, on the basis of symptoms, daily activity and lung function, and taking into account the treatment received during this period. The appropriateness of asthma controller therapy in real-world conditions can thus only be evaluated as a function of asthma severity and control. According the request of French health Authorities, the study was put in place in order to assess the appropriateness of ICS treatment of asthma under real world conditions of care in France. Study Period: : inclusion from May 2004 to March CP panel: September 2005 to April 2009 October 2007 : Inclusion reports from both panels, January 2008 : -year report, May 2008 : CP panel -year report, June 2009: final report, March 200: CP panel final report, several exchanges with French health Authorities between May 2008 and June 20, evaluation by French health Authorities between July and December 202 Objectives: Principal objective: to describe the conditions of use of fluticasone propionate and other ICS in real-world practice (general practice and speciality care), according to asthma severity and control in individual patients ages 5 years and older. Secondary objective: to study factors related to the management of patients with asthma. Indication: Asthma. Study Investigators/Centers: Research Methods: To cover the whole range of asthma care in France, the study had two distinct settings, one in primary care and the other in secondary care. For this reason, the study consisted of two independent panels, conducted by different physician groups, one by GPs and one by CPs. The two panels used different procedures for patient recruitment and data collection, and recruited over different, albeit overlapping, periods. However, the same variables were analysed in the same way from both panels. Participating GPs and CPs were selected at random from a list of all licensed physicians. Subjects were recruited during spontaneous consultation for asthma in participating practices. All subjects consulting for asthma during the recruitment period were invited to participate in the study. Subjects were evaluated at the inclusion consultation and at all follow-up consultations for asthma occurring during the two-year follow-up period. At each consultation, current symptoms and treatment were documented. From the data obtained on recent symptoms and current treatments, asthma severity, asthma control and appropriateness of treatment were determined. These three variables were compared between two subgroups of patients, one treated with fluticasone propionate and one with other ICS. Data Source: : data were extracted from the Thalès electronic database. Thalès is a computerised network of,200 GPs who collect exhaustive anonymous data on patient consultations and prescriptions which are entered into a centralised electronic database, allowing subsequent follow-up of outcomes. CP panel: data were entered by investigator into an electronic case report form after the inclusion consultation and after each follow-up consultation. Symptoms and severity data have been collected by GPs. Study Design: Observational, prospective, pharmacoepidemiological study with two years follow-up. Study Population:Diagnosis of asthma Aged at least fifteen years Consultation at least twice in the previous year Prescription of an ICS in the previous six months Consulting specifically for asthma during the recruitment period Providing oral informed consent Diagnosis of COPD, chronic bronchitis, professional pulmonary disease or emphysema Refusal to participate in the study Study Exposures, Outcomes: Study groups: two study groups were constituted, one prescribed fluticasone propionate, the other prescribed another

2 ICS. Choice of treatment: the choice of ICS (fluticasone propionate or other) was made at the investigator s discretion prior to and independently of participation in the study. Modification of treatment: asthma treatment could be modified at any time during the study and for whatever reason at the investigator s discretion. Outcome measures: (i) asthma severity Asthma severity was evaluated using the following algorithm, which was designed by the Scientific Committee of the study and subsequently validated by the French Health Authorities: Asthma severity was assessed at each consultation and classified as intermittent, mild persistent, moderate persistent or severe persistent, based on the GINA 2004 clinical (C) and therapeutic (T) classifications. The algorithm took into account all consultations for each patient, and assessed the overall asthma severity level. The assessment of asthma severity over the two-year period did not take into account whether treatment seemed appropriate for the severity grade. (ii) asthma control Asthma control was assigned on the basis of symptoms reported in the previous three works as defined in the 2004 ANAES guidelines. Control was defined as either acceptable or unacceptable. This parameter was assessed at inclusion and at the last consultation recorded in the study. In the CP panel only, asthma control was also determined using patient reported outcome measures Asthma Control Test Asthma Control Questionnaire (iii) appropriateness of treatment Appropriateness of treatment was assessed in terms of compliance with national guidelines in force at the time of the study (ANAES 2004) and was evaluated by analysing therapeutic strategies implemented by participating physicians between inclusion and the first follow-up visit. Appropriate level of treatment intensity: therapeutic (T) severity classification superior or equivalent to clinical (C) severity classification Inadequate level of treatment intensity: therapeutic (T) classification inferior to clinical (C) classification Excessive level of treatment: intensity: therapeutic (T) classification at least two grades superior to clinical (C) classification without an apparent clinical rationale Other relevant variables documented: Type and dose (defined as beclomethasone equivalents, according to the 2004 GINA guidelines) of ICS prescribed Changes to ICS treatment during follow-up Presence of asthma risk factors Lung function (peak expiratory flow rate) Data Analysis Methods: with the management of patients with asthma (type of ICS prescribed) were evaluated using multivariate regression analysis. Two models were investigated. The first deterministic model included four variables, namely gender, age group, smoking status and asthma severity. The second exploratory model included, together with asthma severity as a covariate, all variables significantly associated with treatment group that had been identified in a preliminary bivariate analysis adjusted for severity. Limitations: Information on consultations for asthma by other physicians is not documented in the Thalès database, and treatment changes made by other physicians are thus not documented. The participation of CPs being voluntary, this may have led to selection of physicians whose treatment practice is not representative of all CPs in France. To respect the observational nature of the study, no follow-up visits were organised specifically for the needs of the study. This is a potential source of significant loss of subjects to follow-up. Study Results: 2

3 Study participants N (87.6%) 748 (2.4%) 666 (3.4%) 6 (70.0%) 924 (82.8%) CP panel 44 (47.7%) 483 (52.3%) N (98.%) 500 (88.3%) 465 (93.0%) 206 (44.3%) 259 (56.7%) Demographics/Baseline Characteristics Subjects included in the CP panel were similar to those included in the with respect to age, gender and disease duration. However, the CP panel comprised fewer current smokers than the (8.2% versus 6.7%) and more subjects with documented atopic asthma (69.4% versus 5.8%). GP Panel Age (years; mean ± SD) Age (years; median [range]) Gender (% women) Duration of asthma (years; mean ± SD) Duration of asthma (years; median [range]) Smoking status (% current smoker) Type of asthma (% atopic asthma) Asthma severity assessed by the investigator (N = 44) 52.3 ± [5 92]253 (57.4%)8.8 ± 4.65 [ 75]70 (5.9%) 236 (53.5%) 25 (5.7%) 39 (8.8%) 49 (33.8%) 228 (5.7%) 54.8 ± [5 93] 278 (57.6%) 7.7 ± [ 80] 84 (7.4%) 243 (50.3%) 35 (7.2%) 7 (4.7%) 238 (49.3%) 39 (28.8%) 3

4 CP Panel Age (years; mean ± SD) Age (years; median [range]) Gender (% women) Duration of asthma (years; mean ± SD) Duration of asthma (years; median [range]) Smoking status (% current smoker) Type of asthma (% atopic asthma) Asthma severity assessed by the investigator ICS treatment 47.4 ± [5-8] 9 (57.8%) 8.9 ± [ 6] 22 (0.7%) 49 (73.0%) 2 (.0%) 7 (8.3%) 63 (30.6%) 24 (60.2%) 49.4 ± [6 85] 67 (64.5%) 8.9 ± [ 70] 6 (6.2%) 69 (66.5%) (0.4%) 26 (0.0%) 32 (5.0%) 00 (38.6%) Low dose Intermediate dose High dose ICS alone Free ICS/LABA combination FIxed ICS/LABA combination Prescribed ICS at last follow-up visit CP panel Low dose Intermediate dose High dose ICS alone Free ICS/LABA combination FIxed ICS/LABA combination (N = 44) 6 (3.6%) 44 (32.7%) 28 (63.7%) 28 (6.3%) 48 (0.9%) 365 (82.8%) 330 (74.8%) 6 (7.8%) 58 (28.2%) 32 (64.%) 5 (7.3%) 22 (0.7%) 69 (82.0%) 49 (30.8%) 287 (59.4%) 47 (9.7%) 53 (3.7%) 22 (25.3%) 208 (43.%) 323 (66.9%) 78 (3.0%) 20 (46.3%) 6 (23.6%) 39 (5.%) 74 (28.6%) 46 (56.4%) Prescribed ICS at last follow-up visit 20 (97.5%) 244 (94.2%) Outcome: asthma severity The majority of subjects were classified as having moderate or severe persistent asthma at inclusion (80% overall for the and 90% overall for the CP panel). Subjects treated with fluticasone propionate were more frequently classified as having severe persistent asthma than subjects treated with other ICS. (N = 44) 5.7% [3.5% - 7.8%] 8.8% [6.2% -.5%] 33.8% [29.4% %] 5.7% [47.0% %] 7.2% [4.9% - 9.6%] 4.7% [.5% - 7.9%] 49.3% [44.8% %] 28.8% [24.7% %] 4

5 CP panel.0% [0% - 2.3%] 8.3% [4.5% - 2%] 30.6% [24.3% %] 60.2% [53.5% %] 0.4% [0% -.%] 0.0% [6.4% - 3.7%] 5.0% [44.9% - 57.%] 38.6% [32.7% %] Outcome: asthma control According to the ANAES criteria, asthma control at inclusion was considered unacceptable in around three-quarters of subjects. No differences were observed in the proportion of subjects with acceptable control, which was similar between subjects in the and subjects in the CP panel and between subjects treated with fluticasone propionate and subjects treated with another ICS. The proportion of subjects whose asthma control was acceptable both at inclusion and at last follow-up ranged from 0% to 6%, according to the group and panel. In the CP panel, asthma control was also evaluated using patient-reported outcome measures. Asthma control at inclusion was acceptable in 57% of subjects according to the ACT and in 38% according to the ACQ. : control at inclusion (ANAES) Evolution of control between inclusion and last visit at both visits at inclusion/unacceptable at last follow-up visit at inclusion/acceptable at last follow-up visit Uncceptable at both visits CP panel: control at inclusion (ANAES) Evolution of control between inclusion and last visit at both visits at inclusion/unacceptable at last follow-up visit at inclusion/acceptable at last follow-up visit Uncceptable at both visits Control at inclusion (ACT) Control at inclusion (ACQ) (N = 44) 23.4% [9.4% %] 76.6% [72.7% %] (N = 44) 43 (9.8%) 94 (2.3%) 60 (3.8%) 244 (55.3%) 23.4% [7.6% %] 76.6% [70.8% %] (N = 203) 25 (2.%) 23 (.3%) 37 (8.2%) 8 (58.%) (N = 82) 99 (54.4%) 83 (45.6%) (N = 80) 70 (38.9%) 0 (6.%) 25.% [2.2% %] 75.0% [7.% %] 66 (3.7%) 55 (.4%) 3 (23.4% 249 (5.6%) 24.4% [9.% %] 75.6% [70.3% %] (N = 247) 39 (5.8%) 2 (8.5%) 44 (7.8%) 43 (57.9%) (N = 232) 36 (58.6%) 96 (4.4%) (N = 238) 89 (37.4%) 49 (62.6%) 5

6 Outcome: appropriateness of treatment For the majority of subjects, the intensity of ICS treatment at inclusion was considered appropriate for the severity of the underlying asthma. The proportion of subjects whose treatment was considered to be appropriate was higher for the CP panel than for the, and higher for subjects who were prescribed fluticasone propionate than for subjects prescribed another ICS. Subjects treated with other ICS were more frequently treated at an inadequate intensity. Inadequate Appropriate Excessive CP panel Inadequate Appropriate Excessive (N = 44) 25.9% [2.8% %] 64.2% [59.7% %] 0.0% [7.2% - 2.8%] 4.6% [9.7% - 9.4%] 79.% [73.6% %] 6.3% [3.0% - 9.6%] 4.6% [37.2% %] 50.7% [46.3% %] 7.7% [5.3% - 0.0%] 3.7% [26.0% %] 62.5% [56.7% %] 5.8% [2.9% - 8.6%] Factors associated with type of ICS treatment In both the deterministic and the exploratory models and in both the GP and CP panels, asthma severity as determined by the study algorithm, was strongly associated with the type of ICS prescribed (p <0.000). Subjects with more severe asthma were more likely to be prescribed fluticasone propionate than another ICS. In the, a weaker association (p = 0.008) was also observed with age as a continuous variable, with younger subjects being more likely to be prescribed fluticasone propionate. Deterministic model Gender (women versus men) Age group (by quartile) <35 years (reference) 35 to 48 years 49-6 years >6 years Smoking status (smokers versus non-smokers) (reference) Exploratory model Age (continuous variable) (reference) Odds ratio [95% CI] 0,993 [0,757 -,302] 0,790 [0,538 -,6] 0,69 [0,470 -,04] 0,58 [0,39-0,864] 0,778 [0,536 -,30] 0,820 [0,428 -,572] 0,927 [0,530 -,62] 2,54 [,432-4,44] 0,990 [0,983-0,997] 0,837 [0,437 -,603] 0,923 [0,529 -,60] 2,52 [,438-4,427] p 0,96 0,05 0,9 < 0,000 0,008 < 0,000 6

7 CP panel Odds ratio [95% CI] p Deterministic model Gender (women versus men) Age group (by quartile) <35 years (reference) 35 to 48 years 49-6 years >6 years Smoking status (smokers versus non-smokers) (reference) or intermittent Exploratory model (reference) or intermittent [ ].240 [ ] [ ] [ ].672 [ ] [ ] [ ] [ ] [ ] < < Conclusion: In this study performed in primary and specialist care in France, fluticasone propionate accounted for 44.7% of all ICS use in the patients recruited into the (n=924) and 44.3% in the CP patients recruited into the panel (n=577). Treatment with fluticasone propionate was rated as appropriate for the severity of asthma in 64% () and 79% (CP panel) of cases based upon available data and the severity algorithm. Asthma control was deemed unacceptable in three-quarters of subjects (both panels), illustrating the need for a more dynamic approach to asthma management as recommended in the GINA guidelines. Treatment with fluticasone propionate was appropriate for the severity of asthma in a higher proportion of subjects than was the case for other ICS (, 64% vs 5%, CP panel, 79% vs 62%). Less than 0% of subjects were apparently using ICS at an excessively high treatment intensity. was more frequently used in subjects with more severe asthma than, and more frequently used at a higher dose consistent with the greater severity. Otherwise, no other substantial differences in clinical or demographic characteristics were observed between subjects prescribed fluticasone propionate and those prescribed other ICS in this study of patients treated by GP and CP healthcare settings in France. 7

A Disease Management Program in France : Lessons from the RESALIS Experiment 18 Months Before and 12 Months After Public Health Interventions

A Disease Management Program in France : Lessons from the RESALIS Experiment 18 Months Before and 12 Months After Public Health Interventions 4 th European Conference on Health Economics Université Paris V. 7-10 July 2002 A Disease Management Program in France : Lessons from the RESALIS Experiment 18 Months Before and 12 Months After Public

More information

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation

More information

6.1 Summary and implications of findings

6.1 Summary and implications of findings 6 Conclusions Key points Many people for whom asthma management guidelines would recommend using inhaled corticosteroids are not using them regularly. At the same time, most inhaled corticosteroids that

More information

Standardizing the measurement of drug exposure

Standardizing the measurement of drug exposure Standardizing the measurement of drug exposure The ability to determine drug exposure in real-world clinical practice enables important insights for the optimal use of medicines and healthcare resources.

More information

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age

Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Classifying Asthma Severity and Initiating Treatment in Children 0 4 Years of Age Components of Severity Symptoms Intermittent 2 days/week Classification of Asthma Severity (0 4 years of age) Persistent

More information

Inhaled Corticosteroids and the Risks

Inhaled Corticosteroids and the Risks Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression Journal Club October 13, 2010 By Anya Litvak, Kik Keiko Greenberg, and Jonathan Chrispin Background Inhaled corticosteroids are commonly

More information

Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles

Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology. Presented by: Elisa Cascade, MediGuard/Quintiles Leveraging Social Networks to Conduct Observational Research: A Paradigm Shift in Methodology Presented by: Elisa Cascade, MediGuard/Quintiles About Elisa Cascade, VP MediGuard/Quintiles Assisted in site

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

Managing Asthma Long Term

Managing Asthma Long Term Managing Asthma Long Term TARGET POPULATION Eligibility Inclusion Criterion Exclusion Criterion RECOMMENDATIONS F I G U R E 4 2 a. CLASSIFYING ASTHMA SEVERITY AND INITIATING TREATME N T IN CHILDREN 0 4

More information

What you need to know about Reading your Pulmonary Function Report. A typical Pulmonary Function report usually has four and sometime five sections.

What you need to know about Reading your Pulmonary Function Report. A typical Pulmonary Function report usually has four and sometime five sections. A typical Pulmonary Function report usually has four and sometime five sections. Demographics Test results Graphs Interpretation Trends (less commonly included) Although the order that these sections are

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance

Chronic obstructive pulmonary disease. Costing report. Implementing NICE guidance Chronic obstructive pulmonary disease Costing report Implementing NICE guidance February 2011 NICE clinical guideline 101 National costing report: chronic obstructive pulmonary disease 1 of 30 This costing

More information

Service Specification

Service Specification Service Specification Spirometry in Primary Care Date: February 2011 Document Reference: Service Specification (V4.0) Contents: Section Page 1 Definition of service 3 2 Training 4 3 Reporting / Monitoring

More information

Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)

Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) Quality Improvement Support: Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD) The Aims and Measures section is intended to provide protocol users with a menu of measures for multiple

More information

Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association.

Asthma Intervention. An Independent Licensee of the Blue Cross and Blue Shield Association. Asthma Intervention 1. Primary disease education Member will have an increased understanding of asthma and the classification by severity, the risks and the complications. Define asthma Explain how lungs

More information

Use of routinely collected electronic healthcare data: Lessons Learned

Use of routinely collected electronic healthcare data: Lessons Learned Use of routinely collected electronic healthcare data: Lessons Learned Massoud Toussi, MD, PhD, MBA European lead, Pharmacoepidemiology and Safety Real World Evidence Solutions, IMS Health, France ENCePP

More information

Article details. Abstract. Version 1

Article details. Abstract. Version 1 Article details Title Authors Abstract Version 1 Osteoarthritis in Family Physician Practices in Canada: A Report of the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) Morkem, Rachael; Birtwhistle,

More information

This supplementary material has been provided by the authors to give readers additional information about their work.

This supplementary material has been provided by the authors to give readers additional information about their work. SUPPLEMENTAL MATERIAL Table S1. The logistic regression model used to calculate the propensity score. Table S2. Distribution of propensity score among the treat and control groups of the full and matched

More information

Drug: mepolizumab (Nucala) Class: Interleukin-5 Receptor Antagonist Line of Business: Non-Medicare Effective Date: February 17, 2016.

Drug: mepolizumab (Nucala) Class: Interleukin-5 Receptor Antagonist Line of Business: Non-Medicare Effective Date: February 17, 2016. This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Which smokers develop COPD? A prediction rule. Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW

Which smokers develop COPD? A prediction rule. Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW 5 Which smokers develop COPD? A prediction rule Geijer RMM Sachs APE Verheij TJM Zuithoff, NPA Lammers J-WJ Hoes AW 54 Prediction of moderate COPD Introduction Tobacco smoking is the main risk factor for

More information

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations ACO #9 Prevention Quality Indicator (PQI): Ambulatory Sensitive Conditions Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Data Source Measure Information Form (MIF)

More information

medicineupdate to find out more about this medicine

medicineupdate to find out more about this medicine medicineupdate Asking the right questions about new medicines Seretide for chronic obstructive pulmonary disease What this medicine is 1 What this medicine treats 2 Other medicines available for this condition

More information

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Brochure More information from http://www.researchandmarkets.com/reports/2989104/ Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Description: Bosatria (Mepolizumab) (Asthma) - Forecast

More information

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Maura Iversen,, PT, DPT, SD, MPH 1,2,3 Ritu Chhabriya,, MSPT 4 Nancy Shadick, MD 2,3 1 Department of Physical Therapy, Northeastern

More information

Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD

Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD Laboratorios Almirall, S.A. and Forest Laboratories, Inc. complete Phase III Studies in COPD BARCELONA, July 7th: Laboratorios Almirall, S.A. and Forest Laboratories, Inc. (NYSE: FRX) have announced that

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing

Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing Differentiating Asthma from COPD: Role of History, Physical Examination, Laboratory Studies, and Lung Function Testing Stephen P Peters, MD, PhD, FAAAAI Professor of Medicine, Pediatrics and Translational

More information

Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol

Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol Does referral from an emergency department to an alcohol treatment center reduce subsequent emergency room visits in patients with alcohol intoxication? Robert Sapien, MD Department of Emergency Medicine

More information

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD

PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD PATIENT GROUP DIRECTION (PGD) ADMINISTRATION OF INHALED SALBUTAMOL FOR THE EMERGENCY TREATMENT OF ACUTE ASTHMA OR COPD EXACERBATION AT HMP FORD Version Number: 01HMP Patient Group Direction originally

More information

Clinical pathway concept - a key to seamless care

Clinical pathway concept - a key to seamless care SECTION 5: PATIENT SAFETY AND QUALITY ASSURANCE 1 Clinical pathway concept - a key to seamless care Audrey Janoly-Dumenil, Hôpital Edouard Herriot, CHU Lyon Marie-Camille Chaumais, Hôpital Antoine Béclère,

More information

VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS

VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS 39 Chapter 3 VITAMIN C AND INFECTIOUS DISEASE: A REVIEW OF THE LITERATURE AND THE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PROSPECTIVE STUDY OVER 8 YEARS Maxine Briggs TABLE OF CONTENTS I. Review of the

More information

Asthma. When do these symptoms arise? What triggers make asthma worse?

Asthma. When do these symptoms arise? What triggers make asthma worse? Asthma Asthma is the term which describes a specific type of breathing problem that arises due to narrowing of the airways. This narrowing is caused when certain natural chemicals within the body are released,

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Straw Breathing Exercise

Straw Breathing Exercise Straw Breathing Exercise Purpose Students breathe though a straw at rest and after exercise to experience what it feels like to have asthma. Overview Students first fill out an anonymous questionnaire

More information

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma

Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Guidance to support the stepwise review of combination inhaled corticosteroid therapy for adults ( 18yrs) in asthma Important Complete asthma control needs to be achieved for at least 12 weeks before attempting

More information

PUBLIC SUMMARY DOCUMENT

PUBLIC SUMMARY DOCUMENT PUBLIC SUMMARY DOCUMENT Product: Budesonide with eformoterol fumarate dihydrate, powder for oral inhalation, fixed dose combination, 400 micrograms-12 micrograms per dose, Symbicort Turbuhaler 400/12 Sponsor:

More information

New Medicines Profile

New Medicines Profile New Medicines Profile November 2013 Issue No. 13/03 / Nasal Spray (Dymista ) Concise evaluated information to support the managed entry of new medicines in the NHS Summary /fluticasone nasal spray (Dymista

More information

Disparities in Realized Access: Patterns of Health Services Utilization by Insurance Status among Children with Asthma in Puerto Rico

Disparities in Realized Access: Patterns of Health Services Utilization by Insurance Status among Children with Asthma in Puerto Rico Disparities in Realized Access: Patterns of Health Services Utilization by Insurance Status among Children with Asthma in Puerto Rico Ruth Ríos-Motta, PhD, José A. Capriles-Quirós, MD, MPH, MHSA, Mario

More information

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital

Factors Associated with Underutilization of Inhalation Corticosteroids. among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital Factors Associated with Underutilization of Inhalation Corticosteroids among Asthmatic Patients Attending Tikur Anbessa Specialized Hospital By: Yohanes Ayele (B. Pharm) A thesis submitted to the School

More information

Spirometry: Performance and Interpretation. A Guide for General Practitioners

Spirometry: Performance and Interpretation. A Guide for General Practitioners Irish Thoracic Society Spirometry: Performance and Interpretation A Guide for General Practitioners Dr. Terry O Connor, Consultant Respiratory Physician, Mercy University Hospital, Cork Dr. Pat Manning,

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy PAGE: Page 1 of 5 DESCRIPTION: Asthma is a heterogeneous syndrome that might be better described as a constellation of phenotypes, each with distinct cellular and molecular mechanisms, rather than as a

More information

March 28 2011 ABSTRACT

March 28 2011 ABSTRACT March 28 2011 A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix - A first and preliminary report, by the Medical Products Agency.

More information

Coventry & Warwickshire Area Prescribing Committee

Coventry & Warwickshire Area Prescribing Committee Coventry & Warwickshire Area Prescribing Committee Guidance on the use of pimecrolimus cream and tacrolimus ointment in moderate to severe atopic dermatitis This should be read in conjunction with the

More information

Use of Spirometry Testing in the Assessment and Diagnosis of COPD

Use of Spirometry Testing in the Assessment and Diagnosis of COPD Use of Spirometry Testing in the Assessment and Diagnosis of COPD The percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who

More information

STATISTICAL BRIEF #378

STATISTICAL BRIEF #378 STATISTICAL BRIEF #378 July 212 Asthma Medication Use among Adults with Reported Treatment for Asthma, United States, and 28-29 Frances M. Chevarley, PhD Introduction Asthma is a chronic respiratory disease

More information

WAY OF WORKING LUNG PATIENTS

WAY OF WORKING LUNG PATIENTS WAY OF WORKING LUNG PATIENTS CELLO Leiden May 2011 Introduction CELLO, the cooperation of primary health care practitioners in Leiden and surroundings, is an organisation of independently working general

More information

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity

More information

Table E1: Antibiotic use in infancy and wheeze and asthma: longitudinal studies until January 2010

Table E1: Antibiotic use in infancy and wheeze and asthma: longitudinal studies until January 2010 Table E1: Antibiotic use in infancy and wheeze and asthma: longitudinal studies until January 2010 Mai 2010, Sweden [32] Dom 2010, Belgium [33] Su 2010, USA [34] Sobko 2010, Sweden [49] Schmitt 2009, Germany

More information

OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:

OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: 2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive

More information

The American Cancer Society Cancer Prevention Study I: 12-Year Followup

The American Cancer Society Cancer Prevention Study I: 12-Year Followup Chapter 3 The American Cancer Society Cancer Prevention Study I: 12-Year Followup of 1 Million Men and Women David M. Burns, Thomas G. Shanks, Won Choi, Michael J. Thun, Clark W. Heath, Jr., and Lawrence

More information

The economic burden of lung disease in Europe. Online supplement.

The economic burden of lung disease in Europe. Online supplement. The economic burden of lung disease in Europe. Online supplement. 1. Introduction A bottom-up prevalence-based costing approach was used to estimate the economic burden of lung disease, using a methodology

More information

National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry

National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry National Emphysema Treatment Trial (NETT) Consent for Screening and Patient Registry Instructions: This consent statement is to be signed and dated by the patient in the presence of a certified study staff

More information

Breathe With Ease. Asthma Disease Management Program

Breathe With Ease. Asthma Disease Management Program Breathe With Ease Asthma Disease Management Program MOLINA Breathe With Ease Pediatric and Adult Asthma Disease Management Program Background According to the National Asthma Education and Prevention Program

More information

The use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS)

The use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS) RESEARCH Original article... Q The use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS) Lathy Prabhakaran*, Wai Yan Chee*, Kia Chong Chua,

More information

Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders?

Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders? Executive Summary The issue of ascertaining the temporal relationship between problem gambling and cooccurring disorders is an important one. By understanding the connection between problem gambling and

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT

More information

Electronic patient diaries in clinical research

Electronic patient diaries in clinical research Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome

More information

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence 1.0 Abstract Title Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients with Psoriasis Severe or Moderate with Adalimumab Treatment (TOGETHER). Keywords Psoriasis,

More information

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family Am I an Alpha-1 Carrier? 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS

PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS PRINCIPLES ON RESPONSIBLE SHARING OF TRUTHFUL AND NON-MISLEADING INFORMATION ABOUT MEDICINES WITH HEALTH CARE PROFESSIONALS AND PAYERS INTRODUCTION In the era of data-driven medicine, where all parties

More information

New inhaled drugs for asthma & COPD: integration into UK practice

New inhaled drugs for asthma & COPD: integration into UK practice New inhaled drugs for asthma & COPD: integration into UK practice Hasanin Khachi Lead Pharmacist - Respiratory Medicine Joint Chair UKCPA Respiratory Group Barts Health NHS Trust 30 th September 2014 Outline

More information

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

More information

Coding Guidelines for Certain Respiratory Care Services July 2014

Coding Guidelines for Certain Respiratory Care Services July 2014 Coding Guidelines for Certain Respiratory Care Services Overview From time to time the AARC receives inquiries about respiratory-related coding and coverage issues through its Help Line or Coding Listserv.

More information

Sandwell Community Respiratory Service

Sandwell Community Respiratory Service Contents Page Community Respiratory Service 2 Service times and locations 3 Oxygen Service 4 Pulmonary Rehabilitation 5 Maintenance Programme 6 Occupational Therapy 7 Dietary support and advice 7 Weatherwise

More information

Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15

Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15 Wandsworth Respiratory Clinical Reference Group Annual Progress Report 2014/15 April 2015 Dr Kieron Earney & Kate Symons Acknowledgements Dr Sarah Deedat Public Health Lead for Long Term Conditions 1 1.

More information

Where kids come first. Childhood asthma

Where kids come first. Childhood asthma 14 Where kids come first Childhood asthma In Canada, childhood asthma has quadrupled in the last decade. It is one of the most common reasons children are hospitalized or visit emergency departments. A

More information

The Annual Direct Care of Asthma

The Annual Direct Care of Asthma The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a

More information

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION What is Alpha-1? A family history... of lung disease? of liver disease? What you need to know about Alpha-1 Antitrypsin Deficiency 1 ALPHA-1 FOUNDATION What is Alpha-1? Alpha-1 Antitrypsin Deficiency (Alpha-1)

More information

COHORTE-OMG - Observatory of General Medicine - Cohort of

COHORTE-OMG - Observatory of General Medicine - Cohort of COHORTE-OMG - Observatory of General Medicine - Cohort of Patients Consulting Their Treating Physician Head : Clerc Pascal, CERMES (INSERM CNRS U750) Boisnault, EQUIPE PROSPERE Szidon, EQUIPE PROSPERE

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute

More information

A Guide for the Utilization of HIRA National Patient Samples. Logyoung Kim, Jee-Ae Kim, Sanghyun Kim. Health Insurance Review and Assessment Service

A Guide for the Utilization of HIRA National Patient Samples. Logyoung Kim, Jee-Ae Kim, Sanghyun Kim. Health Insurance Review and Assessment Service A Guide for the Utilization of HIRA National Patient Samples Logyoung Kim, Jee-Ae Kim, Sanghyun Kim (Health Insurance Review and Assessment Service) Jee-Ae Kim (Corresponding author) Senior Research Fellow

More information

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION MEPOLIZUMAB (Nucala GlaxoSmithKline Inc.) Indication: Severe eosinophilic asthma Recommendation: The CADTH Canadian Drug Expert Committee (CDEC)

More information

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Harvard Vanguard Medical Associates Case Study Organization Profile Founded in the 1960s, Harvard Vanguard Medical

More information

Written Example for Research Question: How is caffeine consumption associated with memory?

Written Example for Research Question: How is caffeine consumption associated with memory? Guide to Writing Your Primary Research Paper Your Research Report should be divided into sections with these headings: Abstract, Introduction, Methods, Results, Discussion, and References. Introduction:

More information

Annicka G. M. van der Plas. Kris C. Vissers. Anneke L. Francke. Gé A. Donker. Wim J. J. Jansen. Luc Deliens. Bregje D. Onwuteaka-Philipsen

Annicka G. M. van der Plas. Kris C. Vissers. Anneke L. Francke. Gé A. Donker. Wim J. J. Jansen. Luc Deliens. Bregje D. Onwuteaka-Philipsen CHAPTER 8. INVOLVEMENT OF A CASE MANAGER IN PALLIATIVE CARE REDUCES HOSPITALISATIONS AT THE END OF LIFE IN CANCER PATIENTS; A MORTALITY FOLLOW-BACK STUDY IN PRIMARY CARE. Annicka G. M. van der Plas Kris

More information

Marcus Wilson, PharmD. First Plenary Session

Marcus Wilson, PharmD. First Plenary Session Moderator First Plenary Session THE USE OF "BIG DATA" - WHERE ARE WE AND WHAT DOES THE FUTURE HOLD? Marcus Wilson, PharmD HealthCore Wilmington, DE, USA Speakers First Plenary Session THE USE OF "BIG DATA"

More information

MEDICAL POLICY STATEMENT

MEDICAL POLICY STATEMENT MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 06/15/2011 02/15/2017 03/09/2016 Policy Name Policy Number Xolair/Nucala SRx-0013 Policy Type Medical

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

Completeness of Physician Billing Claims for Diabetes Prevalence Estimation

Completeness of Physician Billing Claims for Diabetes Prevalence Estimation Completeness of Physician Billing Claims for Diabetes Prevalence Estimation Lisa M. Lix 1, John Paul Kuwornu 1, George Kephart 2, Khokan Sikdar 3, Hude Quan 4 1 University of Manitoba; 2 Dalhousie University;

More information

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD) DuPage Medical Group Case Study Organization Profile Established in 1999, DuPage Medical Group (DMG) is a multispecialty

More information

Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks

Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Mepolizumab (Nucala ) for Treatment of Severe Asthma with Eosinophilic Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 18, 2015 Background: The

More information

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,

More information

Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD

Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD Lothian Guideline for Domiciliary Oxygen Therapy Service for COPD This document describes the standard for clinical assessment, prescription, optimal management and follow-up of patients receiving domiciliary

More information

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary

More information

Antipsychotic drugs are the cornerstone of treatment

Antipsychotic drugs are the cornerstone of treatment Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,

More information

2010 QARR QUICK REFERENCE GUIDE Adults

2010 QARR QUICK REFERENCE GUIDE Adults 2010 QARR QUICK REFERENCE GUIDE Adults ADULT MEASURES (19 through 64 years) GUIDELINE HEDIS COMPLIANT CPT/ICD9 CODES DOCUMENTATION TIPS Well Care Access to Ambulatory Care Ensure a preventive or other

More information

PLAN OF ACTION FOR. Physician Name Signature License Date

PLAN OF ACTION FOR. Physician Name Signature License Date PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes

More information

Patients Satisfaction with Partial Denture Therapy

Patients Satisfaction with Partial Denture Therapy Patients Satisfaction with Partial Denture Therapy Dubravka KnezoviÊ-ZlatariÊ 1 Asja»elebiÊ 1 Melita ValentiÊ-PeruzoviÊ 1 Vjekoslav Jerolimov 1 Robert eliê 1 Irina FilipoviÊ-Zore 2 Iva Alajbeg 1 1 Department

More information

SYNOPSIS. Risperidone: Clinical Study Report CR003274

SYNOPSIS. Risperidone: Clinical Study Report CR003274 SYNOPSIS Protocol No: CR003274 Title of Study: An Open-Label, Long-Term Trial of Risperidone Long-Acting Microspheres in the Treatment of Subjects Diagnosed with Schizophrenia Coordinating Investigator:

More information

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management

Prior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim

More information

Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease in Korea

Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease in Korea ORIGINAL ARTICLE Medicine General & Social Medicine DOI: 10.3346/jkms.2010.25.9.1259 J Korean Med Sci 2010; 25: 1259-1271 Continuity of Care for Elderly Patients with Diabetes Mellitus, Hypertension, Asthma,

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Spirometry, COPD and lung cancer

Spirometry, COPD and lung cancer Spirometry, COPD and lung cancer Associate Professor Robert Young BMedSc, MBChB, DPhil (Oxon), FRACP, FRCP University of Auckland, New Zealand Spirometry for those with smoking and dust exposures Risk

More information

Asthma and COPD Diagnoses and prescriptions in Swedish primary care

Asthma and COPD Diagnoses and prescriptions in Swedish primary care Asthma and COPD Diagnoses and prescriptions in Swedish primary care Paolina Weidinger Department of Primary Health Care Institute of Medicine Sahlgrenska Academy at University of Gothenburg Gothenburg

More information